Application of MRNA Technology in Cancer Therapeutics

Overview

Journal Vaccines (Basel)

Date 2022 Aug 26

PMID 36016150

Authors

Yesim Eralp

Affiliations

Soon will be listed here.

Abstract

mRNA-based therapeutics pose as promising treatment strategies for cancer immunotherapy. Improvements in materials and technology of delivery systems have helped to overcome major obstacles in generating a sufficient immune response required to fight a specific type of cancer. Several in vivo models and early clinical studies have suggested that various mRNA treatment platforms can induce cancer-specific cytolytic activity, leading to numerous clinical trials to determine the optimal method of combinations and sequencing with already established agents in cancer treatment. Nevertheless, further research is required to optimize RNA stabilization, delivery platforms, and improve clinical efficacy by interacting with the tumor microenvironment to induce a long-term antitumor response. This review provides a comprehensive summary of the available evidence on the recent advances and efforts to overcome existing challenges of mRNA-based treatment strategies, and how these efforts play key roles in offering perceptive insights into future considerations for clinical application.

Citing Articles

Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials.

Karimi-Sani I, Molavi Z, Naderi S, Mirmajidi S, Zare I, Naeimzadeh Y J Nanobiotechnology. 2024; 22(1):601.

PMID: 39367418 PMC: 11453023. DOI: 10.1186/s12951-024-02882-x.

Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy.

Katopodi T, Petanidis S, Grigoriadou E, Anestakis D, Charalampidis C, Chatziprodromidou I Pharmaceutics. 2024; 16(4).

PMID: 38675116 PMC: 11053579. DOI: 10.3390/pharmaceutics16040455.

mRNA: A promising platform for cancer immunotherapy.

Kong B, Kim Y, Kim E, Suk J, Yang Y Adv Drug Deliv Rev. 2023; 199:114993.

PMID: 37414361 PMC: 11797636. DOI: 10.1016/j.addr.2023.114993.

Nanomaterials for mRNA-based therapeutics: Challenges and opportunities.

Li D, Liu Q, Yang M, Xu H, Zhu M, Zhang Y Bioeng Transl Med. 2023; 8(3):e10492.

PMID: 37206219 PMC: 10189457. DOI: 10.1002/btm2.10492.

References

Chen Q, Qi R, Chen X, Yang X, Wu S, Xiao H . A Targeted and Stable Polymeric Nanoformulation Enhances Systemic Delivery of mRNA to Tumors. Mol Ther. 2017; 25(1):92-101. PMC: 5363296. DOI: 10.1016/j.ymthe.2016.10.006. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Jansen Y, Kruse V, Corthals J, Schats K, Van Dam P, Seremet T . A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother. 2020; 69(12):2589-2598. PMC: 11027452. DOI: 10.1007/s00262-020-02618-4. View

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon P, Kandalaft L . Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol. 2019; 10:766. PMC: 6470191. DOI: 10.3389/fimmu.2019.00766. View

Kallen K, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A . A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccin Immunother. 2013; 9(10):2263-76. PMC: 3906413. DOI: 10.4161/hv.25181. View

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

Kruger S, Ilmer M, Kobold S, Cadilha B, Endres S, Ormanns S . Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res. 2019; 38(1):268. PMC: 6585101. DOI: 10.1186/s13046-019-1266-0. View

Crosby E, Hobeika A, Niedzwiecki D, Rushing C, Hsu D, Berglund P . Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. J Immunother Cancer. 2020; 8(2). PMC: 7661359. DOI: 10.1136/jitc-2020-001662. View

Waldmann T . The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy. Cancer Immunol Res. 2015; 3(3):219-27. PMC: 4351780. DOI: 10.1158/2326-6066.CIR-15-0009. View

10.

Uchida S, Kinoh H, Ishii T, Matsui A, Tockary T, Takeda K . Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials. 2016; 82:221-8. DOI: 10.1016/j.biomaterials.2015.12.031. View

11.

Etxeberria I, Bolanos E, Quetglas J, Gros A, Villanueva A, Palomero J . Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8 T Cells. Cancer Cell. 2019; 36(6):613-629.e7. DOI: 10.1016/j.ccell.2019.10.006. View

12.

Rajan T, Gugliandolo A, Bramanti P, Mazzon E . In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update. Int J Mol Sci. 2020; 21(18). PMC: 7556036. DOI: 10.3390/ijms21186514. View

13.

Fritsch E, Burkhardt U, Hacohen N, Wu C . Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res. 2020; 8(12):1465-1469. PMC: 7717540. DOI: 10.1158/2326-6066.CIR-20-0526. View

14.

Liu J, Zhou G, Zhang L, Zhao Q . Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. Front Immunol. 2019; 10:456. PMC: 6433930. DOI: 10.3389/fimmu.2019.00456. View

15.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

16.

Hewitt S, Bailey D, Zielinski J, Apte A, Musenge F, Karp R . Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020; 26(23):6284-6298. DOI: 10.1158/1078-0432.CCR-20-0472. View

17.

Reissmann S . Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci. 2014; 20(10):760-84. DOI: 10.1002/psc.2672. View

18.

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

19.

Spiess C, Zhai Q, Carter P . Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015; 67(2 Pt A):95-106. DOI: 10.1016/j.molimm.2015.01.003. View

20.

Lundstrom K . Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer. Vaccines (Basel). 2021; 9(10). PMC: 8541504. DOI: 10.3390/vaccines9101187. View